Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy

Demonstrates potential of stem cell memory T cells (T_SCM), a key differentiator for Poseida's CAR-T programs 

Read more at prnewswire.com